Affordable Access

deepdyve-link
Publisher Website

Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidate.

Authors
  • Di Fabio, Romano1
  • Alvaro, Giuseppe
  • Braggio, Simone
  • Carletti, Renzo
  • Gerrard, Philip A
  • Griffante, Cristiana
  • Marchioro, Carla
  • Pozzan, Alfonso
  • Melotto, Sergio
  • Poffe, Alessandro
  • Piccoli, Laura
  • Ratti, Emiliangelo
  • Tranquillini, Elvira
  • Trower, Michael
  • Spada, Simone
  • Corsi, Mauro
  • 1 Neurosciences Centre of Excellence for Drug Discovery, Chemical Development and Molecular Discovery Research, GlaxoSmithKline Medicines Research Centre, Via A. Fleming 4, 37135 Verona, Italy. Electronic address: [email protected] , (Italy)
Type
Published Article
Journal
Bioorganic & medicinal chemistry
Publication Date
Nov 01, 2013
Volume
21
Issue
21
Pages
6264–6273
Identifiers
DOI: 10.1016/j.bmc.2013.09.001
PMID: 24075145
Source
Medline
Keywords
License
Unknown

Abstract

The last two decades have provided a large weight of preclinical data implicating the neurokinin-1 receptor (NK1) and its cognate ligand substance P (SP) in a broad range of both central and peripheral disease conditions. However, to date, only the NK1 receptor antagonist aprepitant has been approved as a therapeutic and this is to prevent chemotherapy-induced nausea & vomiting (CINV). The belief remained that the full therapeutic potential of NK1 receptor antagonists had yet to be realized; therefore clinical evidence that NK1 receptor antagonists may be effective in major depression disorder, resulted in a significant further investment in discovering novel CNS penetrant druggable NK1 receptor antagonists to address this condition. At GlaxoSmithKline after the discovery of casopitant, that went on to demonstrate efficacy as a novel antidepressant in the clinic, additional novel analogues of this NK1 receptor antagonist were designed to further enhance its drug developability characteristics. Herein, we therefore describe the discovery process and the vivo pharmacological and pharmacokinetic profile of the new NK1 receptor antagonist 3a (also called orvepitant), selected as clinical candidate and further progressed into clinical studies for major depressive disorder. Moreover, molecular modeling studies enabled us to improve the pharmacophore model of the NK1 receptor antagonists with the identification of a region able to accommodate a variety of heterocycle moieties.

Report this publication

Statistics

Seen <100 times